Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Genzyme’s Lemtrada™ approved in Australia for treatment of multiple sclerosis
Teaching NeuroImages: MRI in advanced neuromyelitis optica.
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of multiple sclerosis
Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.
Vitamin D-dependent rickets, HLA-DRB1, and the risk of multiple sclerosis.
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection.
Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis.
The Many Facets of Cell Injury: Angiogenesis to Autophagy.
Puma, but not noxa is essential for oligodendroglial cell death.
US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight
Dopaminergic Modulation of CD4+CD25 Regulatory T Lymphocytes in Multiple Sclerosis Patients during Interferon-β Therapy.
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
Natalizumab Use During the Third Trimester of Pregnancy.
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis.
Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with MS.
Calcitriol Modulates the CD46 Pathway in T Cells.
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA

Pages